1-adamantyl(piperidino)methanone
1-Adamantyl(piperidino)methanone, also known as **N-piperidin-1-yl-1-adamantanecarboxamide**, is a chemical compound with the formula C16H25NO. It is a white crystalline solid, soluble in organic solvents.
Here's why it's important for research:
**1. Pharmacological Activity:**
* **Anti-inflammatory properties:** Studies have shown that 1-adamantyl(piperidino)methanone exhibits significant anti-inflammatory effects, possibly by inhibiting the production of pro-inflammatory cytokines like TNF-α.
* **Analgesic effects:** This compound has been shown to possess analgesic properties, potentially acting as a potent inhibitor of pain pathways.
* **Neuroprotective effects:** Some research suggests that 1-adamantyl(piperidino)methanone could protect neurons from damage, offering potential therapeutic applications in neurological disorders.
**2. Chemical Structure:**
* **Unique scaffold:** The combination of the adamantane core and the piperidine ring provides a rigid and stable structure, which can be modified to create various derivatives with different pharmacological activities.
* **Versatility:** The compound can be used as a starting material for synthesizing novel drug candidates with enhanced potency and selectivity.
**3. Research Applications:**
* **Drug discovery:** Scientists are actively exploring the potential of 1-adamantyl(piperidino)methanone and its derivatives as promising drug candidates for treating inflammation, pain, and neurological diseases.
* **Structure-activity relationship (SAR) studies:** Researchers utilize this compound to understand how structural modifications affect its biological activity, leading to the development of more effective and targeted drugs.
* **Mechanistic investigations:** Studies are underway to elucidate the precise molecular mechanisms by which this compound exerts its pharmacological effects.
**Overall, 1-adamantyl(piperidino)methanone holds significant promise as a lead compound for drug development in several therapeutic areas. Its unique chemical structure, combined with its promising pharmacological activity, makes it a valuable tool for research and drug discovery.**
**Please note:** This information is for educational purposes only and should not be taken as medical advice. It is important to consult with qualified healthcare professionals for any medical concerns or before making decisions related to your health or treatment.
Cross-References
ID Source | ID |
---|---|
PubMed CID | 584509 |
CHEMBL ID | 245590 |
CHEBI ID | 183758 |
SCHEMBL ID | 3457055 |
SCHEMBL ID | 19841773 |
Synonyms (35)
Synonym |
---|
smr000117086 |
MLS000526612 |
OPREA1_290126 |
adamantan-1-yl-piperidin-1-yl-methanone |
MAYBRIDGE1_008125 |
SR-01000396865-2 |
OPREA1_633750 |
STK125639 |
piperidin-1-yl(tricyclo[3.3.1.1~3,7~]dec-1-yl)methanone |
CHEMBL245590 , |
HMS564J07 |
AKOS000612261 |
bdbm50207772 |
1-adamantyl(piperidin-1-yl)methanone |
CHEBI:183758 |
1-adamantyl(piperidino)methanone |
adamantanyl piperidyl ketone |
HMS2178P18 |
CCG-55067 |
F0020-1641 |
(3r,5r,7r)-adamantan-1-yl(piperidin-1-yl)methanone |
22508-49-2 |
AH-357/03517015 |
1-(1-adamantylcarbonyl)piperidine |
SCHEMBL3457055 |
1-(1-adamantylcarbonyl)piperidine # |
BURUIZXRHQWZQI-UHFFFAOYSA-N |
tricyclo[3,3,1,1(3,7)]decane, 1-piperidylcarbonyl- |
1-(adamantane-1-carbonyl)piperidine |
Z54082320 |
SR-01000396865-1 |
sr-01000396865 |
SCHEMBL19841773 |
BRD-K73970226-001-07-4 |
EN300-15027076 |
Drug Classes (1)
Class | Description |
---|---|
N-acylpiperidine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (5)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0158 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) | IC50 (µMol) | 0.1930 | 0.0041 | 1.0667 | 10.0000 | AID306869 |
Corticosteroid 11-beta-dehydrogenase isozyme 1 | Mus musculus (house mouse) | IC50 (µMol) | 0.1340 | 0.0020 | 0.2410 | 3.7600 | AID306871 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (2)
Process | via Protein(s) | Taxonomy |
---|---|---|
lung development | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
steroid catabolic process | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Molecular Functions (6)
Process | via Protein(s) | Taxonomy |
---|---|---|
protein homodimerization activity | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
7-beta-hydroxysteroid dehydrogenase (NADP+) activity | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
NADP binding | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
11-beta-hydroxysteroid dehydrogenase (NADP+) activity | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
cortisol dehydrogenase activity | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
steroid binding | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Ceullar Components (3)
Process | via Protein(s) | Taxonomy |
---|---|---|
endoplasmic reticulum membrane | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
membrane | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
endoplasmic reticulum membrane | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
intracellular membrane-bounded organelle | Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (19)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID306869 | Inhibition of human 11beta-HSD1 expressed in HEK293 cells after 2 hrs by scintillation proximity assay | 2007 | Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10 | Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. |
AID306870 | Inhibition of human 11beta-HSD2 at 10 uM by scintillation proximity assay | 2007 | Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10 | Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. |
AID306871 | Inhibition of mouse 11beta-HSD1 expressed in CHO cells after 4 hrs by scintillation proximity assay | 2007 | Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10 | Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.04) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |